Alkermes PLC

Alkermes plc amends prior filing to detail compensation and board appointment for Blair C. Jackson as he assumes President and CEO roles.

Alkermes plc announced its second quarter 2026 financial results, reporting $496.0 million in revenue and $139.2 million in Adjusted EBITDA, while also announcing a CEO transition effective August 1, 2026.

Alkermes plc announced the termination of its Authorized Generic Product Supply Agreement with Amneal Pharmaceuticals LLC for a generic version of VIVITROL, effective July 6, 2026.

Alkermes plc announced that its investigational drug, alixorexton, has received orphan drug designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.

Alkermes plc shareholders approved amendments to the 2018 Stock Option and Incentive Plan, increasing authorized shares and re-electing directors at the annual meeting.

Alkermes plc reported positive topline results from its Phase 3 REVITALYZ study, showing LUMRYZ significantly improved symptoms of idiopathic hypersomnia.

Alkermes plc announced its second-quarter 2026 financial results, highlighting revenue growth from LUMRYZ and increased operating expenses due to the Avadel acquisition.

Alkermes plc reported a net loss for the first quarter of 2026, primarily driven by expenses related to the recent acquisition of Avadel Pharmaceuticals, while total revenues saw a significant increase.

Alkermes plc reported a decrease in net income from continuing operations for the nine months ended September 30, 2025, while announcing a definitive agreement to acquire Avadel Pharmaceuticals plc for up to $20.00 per share.

Alkermes plc reported a decrease in overall revenue and net income for Q2 2025 due to expected royalty expirations, while showcasing robust growth in proprietary product sales and advancing its neuroscience pipeline with positive clinical trial results for Alixorexton.

Alkermes' Q1 2025 net income from continuing operations decreased to $22.5 million, impacted by lower manufacturing and royalty revenues, partially offset by increased product sales and reduced operating expenses.

Alkermes plc reported increased product sales but a decrease in manufacturing and royalty revenues for the third quarter of 2024, following the conclusion of a key arbitration and the expiration of a royalty agreement.

Alkermes plc reported a decrease in net income for 2025 despite strong proprietary product sales, driven by expiring royalties and increased R&D investments, while completing a major acquisition and advancing its neuroscience pipeline.

Alkermes plc reports a net income of $372.1 million for 2024, driven by proprietary product sales and strategic collaborations, while managing patent challenges and completing the sale of its Athlone facility.

Alkermes details its ordinary share structure, dividend restrictions, and potential anti-takeover provisions in its latest SEC filing.

Nancy Lynn Snyderman, a Director of Alkermes plc., sold 44,472 shares of common stock on August 3, 2026 for $50.35 per share.

Craig C. Hopkinson, EVP R&D, Chief Medical Officer of Alkermes plc., sold 9,000 shares of common stock on August 3, 2026 for $48.58 per share.

David Joseph Gaffin, EVP, CLO, Alkermes, Inc. of Alkermes plc., sold 2,034 shares of common stock on August 3, 2026 for $48.58 per share.

Alkermes plc reports a Form 4 filing detailing a sale of ordinary shares by executive David Joseph Gaffin, executed under a pre-arranged trading plan.

Alkermes plc reports significant stock transactions by EVP R&D, Craig C. Hopkinson, executed under a pre-arranged trading plan.

Alkermes plc director Christopher I. Wright sold 2,000 ordinary shares at $45.10 per share via a 10b5-1 trading plan.

Alkermes plc has announced its 2026 Annual General Meeting of Shareholders, scheduled for May 20, 2026, to elect directors, approve executive compensation, ratify auditor appointment, and renew board authorities.

Alkermes plc encourages shareholders to vote before the May 21, 2025, annual general meeting.

Alkermes plc will hold its 2025 Annual General Meeting of Shareholders on May 21, 2025, in Dublin, Ireland, to vote on director elections, executive compensation, auditor ratification, and other proposals.

Alkermes plc will hold its 2025 Annual General Meeting on May 21, 2025, to vote on director elections, executive compensation, auditor ratification, and stock plan approval.

Alkermes plc urges shareholders to vote on proposals outlined in the Proxy Statement for the 2024 Annual General Meeting to be held on May 31, 2024.

Alkermes plc will hold its Annual General Meeting of Shareholders on May 31, 2024, to vote on director elections, executive compensation, auditor ratification, and other proposals.

T. Rowe Price Associates, Inc. has filed a Schedule 13G, reporting beneficial ownership of 4,664,563 shares of Alkermes PLC common stock, representing 2.8% of the class.

Vanguard Portfolio Management has reported beneficial ownership of 5.8% of Alkermes PLC's common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 8,676,888 shares, representing 5.21% of Alkermes PLC's common stock as of March 31, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Alkermes PLC following an internal realignment.

State Street Corporation has reported a 5.2% passive beneficial ownership stake in Alkermes PLC, holding 8,540,351 shares as of September 30, 2025.

T. Rowe Price Associates, Inc. has reported a 6.1% beneficial ownership stake in Alkermes PLC, holding over 10 million common shares.